FDA Proposal Limits Compounding of Obesity Drugs

The U.S. Food and Drug Administration on Thursday proposed excluding active ingredients for Novo Nordisk and Eli Lilly’s weight-loss drugs on the list ​of drugs outsourcing facilities can use for compounding. If finalized, ⁠the exclusion would limit ​compounding of these…[#item_full_content]

Related articles

You may also be interested in

Headline

Never Miss A Story

Get our Weekly recap with the latest news, articles and resources.
Cookie policy

We use our own and third party cookies to allow us to understand how the site is used and to support our marketing campaigns.